Ambovex(®) as a novel immunological modulator drug for the treatment of hepatocellular carcinoma (HCC) in the liver: a Phase II clinical trial

Hepatocellular carcinoma (HCC) is a global public health problem, based on it being the fifth most common cancer and third leading cause of cancer-related mortality worldwide. The approved conventional treatment methods for HCC have shown life-threatening side effects with limited or negligible succ...

Descripción completa

Detalles Bibliográficos
Autores principales: Salama, Hosny, Ahmad, Hassan, Elchagea, Ismail, Zekri, Abdel Rahman, Medhat, Eman, Bahnassy, Abeer, Lange, Michael, Rabbat, Mohammed, de la Torre, Andrew N, Punamiya, Pravin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918287/
https://www.ncbi.nlm.nih.gov/pubmed/27508197
http://dx.doi.org/10.2147/JHC.S60864

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918287/
https://www.ncbi.nlm.nih.gov/pubmed/27508197
http://dx.doi.org/10.2147/JHC.S60864

Ejemplares similares